Analysis: Eylea, Lucentis less cost-effective than Avastin for treatment of DME

June 10, 2016

Aflibercept and ranibizumab were less cost-effective than bevacizumab in the treatment of diabetic macular edema, according to a post hoc analysis of data from the Diabetic Retinopathy Clinical Research Network Protocol T trial. “These results highlight the challenges that physicians, patients and policymakers face when safety and efficacy results are at odds with cost-effectiveness results,” the study authors said.

Read the full story >

More News Coverage

Featured Faculty: 
News Type: